مورد إلكتروني
Differentiated Thyroid Cancer in Pediatric Population (≤18 Years): Postoperative Treatment with Radioactive Iodine (I-131)
| العنوان: | Differentiated Thyroid Cancer in Pediatric Population (≤18 Years): Postoperative Treatment with Radioactive Iodine (I-131) |
|---|---|
| عناروين إضافية: | Diferencirani karcinom štitnjače u pedijatrijskoj populaciji (≤18 godina): poslijeoperacijsko liječenje radioaktivnim jodom (I-131) |
| المؤلفون: | Marin Prpić, Maja Franceschi, Tomislav Jukić, Davor Kust, Nina Dabelić, Tea Varjačić, Marko Lucijanić, Ante Bolanča, Zvonko Kusić |
| المصدر: | Acta clinica Croatica; ISSN 0353-9466 (Print); ISSN 1333-9451 (Online); Volume 58.; Issue 1. |
| بيانات النشر: | Sestre Milosrdnice University hospital and Institute of Clinical Medical Research 2019 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | The aim is to present data on the treatment and follow-up in a cohort of patients with pediatric thyroid cancer who underwent total thyroidectomy and received postoperative radioactive iodine (I-131) therapy. The study was conducted in a tertiary high-volume thyroid center, in pediatric patients with differentiated thyroid cancer who were consecutively treated during the 1965-2015 period. A total of 45 patients aged ≤18 years having undergone total thyroidectomy with or without selective neck dissection were included in the study. Decision on postoperative I-131 ablation was based on tumor characteristics, postoperative thyroglobulin level, preablative whole body scintigraphy, and/or neck ultrasound. Median age at diagnosis was 15 years. The presence of cervical lymph node metastases was significantly associated with papillary thyroid cancer, larger tumor size, involvement of two thyroid lobes, and multifocal disease. The presence of distant metastases was significantly associated with larger tumor size. None of the patients died during follow-up period, and the 5-year and 10-year overall survival rates were 100%. The 5-year and 10-year progression-free survival (PFS) rates were 87% and 73%, respectively. Male gender (p=0.046), age ≤15 years (p=0.029) and tumor size >15 mm (p=0.042) were significantly associated with inferior PFS. A significant positive trend of increase in the number of newly diagnosed patients was observed over time (p=0.011). Clinical management of pediatric thyroid cancer is challenging, especially in the light of increasing incidence in this population. Male patients younger than 15 years and with tumors of more than 15 mm in size require additional caution due to lower PFS observed. Cilj je prikazati podatke o liječenju i praćenju kohorte bolesnika s pedijatrijskim rakom štitnjače, kod kojih je učinjena totalna tireoidektomija te provedena poslijeoperacijska terapija radioaktivnim jodom (I-131). Studija je provedena u tercijarnom centru za štitnjaču visokog volumena, u bolesnika s pedijatrijskim diferenciranim karcinomom štitnjače koji su liječeni konsekutivno u razdoblju od 1965. do 2015. godine. U studiju je bilo uključeno 45 bolesnika (18 godina i mlađi) kod kojih je učinjena totalna tireoidektomija sa selektivnom disekcijom vrata ili bez nje. Odluka o indikaciji za provođenje poslijeoperacijske ablacije pomoću I-131 je donesena na temelju karakteristika tumora, poslijeoperacijske razine tireoglobulina, predablacijske scintigrafije cijelog tijela i/ili ultrazvuka vrata. Medijan dobi pri postavljanju dijagnoze je iznosio 15 godina. Prisutnost metastaza u limfne čvorove vrata je bila značajno povezana s papilarnim rakom štitnjače, većom veličinom tumora, zahvaćenosti dvaju režnjeva štitnjače te multifokalnom bolešću. Prisutnost udaljenih metastaza je bila značajno povezana s većom veličinom tumora. Tijekom razdoblja praćenja nijedan bolesnik nije preminuo, a 5-godišnje i 10-godišnje stope ukupnog preživljenja su iznosile 100%. Petogodišnje i 10-godišnje preživljenje bez progresije bolesti (PPB) je iznosilo 87% odnosno 73%. Muški spol (p=0,046), dob ≤15 godina (p=0,029) i veličina tumora >15 mm (p=0,042) su bili značajno povezani s nižim PPB. Zamijećen je značajan trend porasta broja novodijagnosticiranih bolesnika tijekom vremena (p=0,011). Klinički postupak u populaciji dece s diferenciranim karcinomom štitnjače je izazovan, osobito u svjetlu porasta incidencije u ovoj populaciji. Osobitu pozornost treba posvetiti muškim bolesnicima mlađim od 15 godina s tumorima većim od 15 mm zbog opaženog nižeg PPB. |
| مصطلحات الفهرس: | Iodine; Thyroid cancer, papillary; Adenocarcinoma, follicular; Survival rate; Child; Follow-up studies, Jod; Karcinom štitnjače, papilarni; Adenokarcinom, folikularni; Stopa preživljenja; Dijete; Kontrolna istraživanja, text, info:eu-repo/semantics/article, info:eu-repo/semantics/publishedVersion |
| URL: | info:eu-repo/semantics/altIdentifier/doi/10.20471/acc.2019.58.01.16 |
| الإتاحة: | Open access content. Open access content info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/4.0 |
| ملاحظة: | application/pdf English |
| أرقام أخرى: | HRCAK oai:hrcak.srce.hr:220888 1111396842 |
| المصدر المساهم: | HRCAK PORTAL ZNANSTVENIH CASOPISA REPUB From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1111396842 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |